Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | STK33 | Q9BYT3 | 6/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30026859 | 1.00 | RAB9A (1.00) | RAB9ANPC1HSD17B10LMNAGLA | |
| Hydrochloric Acid SCHEMBL30418554 | 0.98 | RAB9A (0.97) | RAB9ANPC1HSD17B10LMNAGLA | |
| SCHEMBL1898900 | 0.84 | NPC1 (0.72) | RAB9ANPC1HSD17B10LMNAGLA | |
| SCHEMBL692427 | 0.81 | RAB9A (0.68) | RAB9ANPC1HSD17B10LMNAGLA | |
| SCHEMBL1901859 | 0.81 | NPC1 (0.68) | RAB9ANPC1HSD17B10LMNAGLA | |
| SCHEMBL1903037 | 0.81 | NPC1 (0.68) | RAB9ANPC1HSD17B10LMNAGLA | |
| SCHEMBL1903735 | 0.81 | NPC1 (0.68) | RAB9ANPC1HSD17B10LMNAGLA | |
| SCHEMBL2135032 | 0.80 | LMNA (0.66) | RAB9ANPC1HSD17B10LMNAGLA | |
| SCHEMBL1898657 | 0.79 | NPC1 (0.65) | RAB9ANPC1HSD17B10LMNAGLA | |
| SCHEMBL1901815 | 0.79 | CASP1 (0.64) | RAB9ANPC1HSD17B10LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2023-03-30 | — | — | US | disclosed |
| US-11472778-B2 | Hepatitis C virus NS3/4A protease inhibitors | UNIVERSITY OF MASSACHUSETTS (US) | 2022-10-18 | — | — | US | disclosed |
| US-20200087265-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2020-03-19 | — | — | US | disclosed |
| US-8962551-B2 | Quinoxalinyl derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962551-B2 | Quinoxalinyl derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2143727-B1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20070021330-A1 | Aza-peptide macrocyclic hepatitis c serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| US-7125845-B2 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1615613-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005112630-A1 | QUINOXALIN-2-ONE DERIVATIVES CROP PROTECTION AGENTS COMPRISING THE SAME AND METHOD FOR PRODUCTION AND USE THEROF | BAYER CROPSCIENCE GMBH (DE) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256000-A1 | Quinoxalin-2-one derivatives, compositions which protect useful plants and comprise these derivatives, and processes for their preparation and their use | BAYER CROPSCIENCE GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
| US-20050065073-A1 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2005010029-A1 | AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005007099-A2 | PKB INHIBITORS AS ANTI-TUMOR AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004093798-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256000-A1 | Quinoxalin-2-one derivatives, compositions which protect useful plants and comprise these derivatives, and processes for their preparation and their use | QSOX1, CYC1, CBR3 | RAB9A 1345/4885NPC1 2934/4885HSD17B10 1307/4885 |
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, CTSC | RAB9A 2677/4885NPC1 368/4885HSD17B10 818/4885 |
| US-11472778-B2 | Hepatitis C virus NS3/4A protease inhibitors | HAVCR2, CTSC, DPP4 | RAB9A 1558/4885NPC1 159/4885HSD17B10 728/4885 |
| US-20070021330-A1 | Aza-peptide macrocyclic hepatitis c serine protease inhibitors | VIP, CTSC, DPP4 | RAB9A 2489/4885NPC1 323/4885HSD17B10 1629/4885 |
| US-20200087265-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | RAB9A 1558/4885NPC1 159/4885HSD17B10 728/4885 |
| US-20050065073-A1 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | VIP, CTSC, PRSS1 | RAB9A 2515/4885NPC1 263/4885HSD17B10 1725/4885 |
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | RAB9A 1558/4885NPC1 159/4885HSD17B10 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.